RTX-003
/ iBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 25, 2021
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
(Businesswire)
- "RubrYc Therapeutics, Inc...announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics. With this transaction, iBio becomes an important strategic investor with its $7.5M investment in the RubrYc’s Series A2 Preferred equity....Additionally, iBio secures exclusive worldwide rights to advance RubrYc’s lead program, RTX-003, a CD25 targeted monoclonal antibody for selective depletion of regulatory T cells in the solid tumor microenvironment."
Licensing / partnership • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1